Advertisement
UK markets close in 2 hours 58 minutes
  • FTSE 100

    8,115.06
    +36.20 (+0.45%)
     
  • FTSE 250

    19,795.14
    +193.16 (+0.99%)
     
  • AIM

    754.66
    +1.54 (+0.20%)
     
  • GBP/EUR

    1.1672
    +0.0016 (+0.13%)
     
  • GBP/USD

    1.2525
    +0.0014 (+0.11%)
     
  • Bitcoin GBP

    51,372.20
    +183.16 (+0.36%)
     
  • CMC Crypto 200

    1,389.21
    -7.32 (-0.52%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    84.21
    +0.64 (+0.77%)
     
  • GOLD FUTURES

    2,355.20
    +12.70 (+0.54%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,052.98
    +135.70 (+0.76%)
     
  • CAC 40

    8,049.03
    +32.38 (+0.40%)
     

How Pfizer Plans to Unlock Another Mass-Market Vaccine

As the first company to introduce a COVID-19 vaccine, pharmaceutical behemoth Pfizer (NYSE: PFE) experienced enormous windfalls by delivering primary and booster shots on a global scale. Now, Pfizer is developing a vaccine for another infectious disease with a wide-open market. Pfizer will invest about $95 million in specialty vaccine maker Valneva, based in France.